Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antinociceptive response in the presence of competitive antagonism: The interaction between tramadol and its active metabolite on μ-opioid agonism and monoamine reuptake inhibition, in the rat

Pharmaceutical Research

Volumn 25, Issue 8, 2008, Pages 1789-1797

  Beier, Horst ^a   Garrido, María J ^b   Christoph, Thomas ^a   Kasel, Dirk ^a   Trocóniz, Iñaki F ^b  

^a GRÜNENTHAL GMBH   (Germany)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Neuropathic pain; Racemic tramadol; Rat model; Semi mechanistic pharmacokinetic pharmacodynamic model

Indexed keywords

DRUG METABOLITE; MONOAMINE; MU OPIATE RECEPTOR; O NORTRAMADOL; SODIUM CHLORIDE; TRAMADOL;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; COMPARTMENT MODEL; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MECHANISM; ENANTIOMER; MALE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; STEADY STATE;

ALGORITHMS; ANALGESICS; ANALGESICS, OPIOID; ANIMALS; BINDING, COMPETITIVE; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLD; DATA INTERPRETATION, STATISTICAL; DRUG INTERACTIONS; MALE; NEUROTRANSMITTER UPTAKE INHIBITORS; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; TRAMADOL;

EID: 46749096465     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9489-8     Document Type: Article

References (34)

1. R. B. Raffa, E. Friderichs, W. Reimann, R. P. Shank, E. E. Codd, and J. L. Vaught. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 260:275-285 (1992).
2. H. H. Hennies, E. Friderichs, and J. Schneider. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 38:877-880 (1988).
3. M. C. Frink, H. H. Hennies, W. Englberger, M. Haurand, and B. Wilffert. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung 46:1029-1036 (1996).
4. M. J. Garrido, M. Valle, M. A. Campanero, R. Calvo, and I. F. Troconiz. Modeling of the in vivo antinociceptive interaction between an opioid agonist, (+)-O-desmethyltramadol, and a monoamine reuptake inhibitor, (-)-O-desmethyltramadol, in rats. J Pharmacol Exp Ther 295:352-359 (2000).
5. B. Driessen, W. Reimann, and H. Giertz. Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro. Br J Pharmacol 108:806-811 (1993).
6. T. A. Bamigbade, C. Davidson, R. M. Langford, and J. A. Stamford. Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth 79:352-356 (1997).
7. M. Valle, M. J. Garrido, J. M. Pavon, R. Calvo, and I. F. Troconiz. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O- desmethyltramadol, in rats. J Pharmacol Exp Ther 293:646-653 (2000).
8. M. J. Garrido, O. Sayar, C. Segura, J. Rapado, M. C. Dios-Vieitez, M. J. Renedo, and I. F. Troconiz. Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity. J Pharmacol Exp Ther 305:710-718 (2003).
9. D. Le Bars, M. Gozariu, and S. W. Cadden. Animal models of nociception. Pharmacol Rev 53:597-652 (2001).
10. M. J. Garrido, W. Habre, F. Rombout, and I. F. Troconiz. Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. Pharm Res 23:2014-2023 (2006).
11. R. S. Pedersen, P. Damkier, and K. Brosen. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther 77:458-467 (2005).
12. S. Laugesen, T. P. Enggaard, R. S. Pedersen, S. H. Sindrup, and K. Brosen. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 77:312-323 (2005).
13. L. Poulsen, L. Arendt-Nielsen, K. Brosen, and S. H. Sindrup. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 60:636-644 (1996).
14. T. Christoph, B. Kögel, W. Strassburger, and S. A. Schug. Tramadol has a better potency ratio relative to morphine in neuropathic than in nociceptive pain models. Drugs R D 8:51-57 (2007).
15. G. J. Bennett, and Y. K. Xie. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33:87-107 (1988).
16. T. Christoph, B. Kögel, K. Schiene, M. Méen, J. De Vry, and E. Friederichs. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 507:87-98 (2005).
17. S. L. Beal, and L. B. Sheiner. NONMEM User's Guides. San Francisco: NONMEM Project Group. University of California, 1998.
18. N. H. Holford. The visual Predictive Check - Superiority to Standard Diagnostic (Rorschach) Plots. PAGE 14 Abstr 738 (2005). www.page-meeting.org/? abstract=738
19. L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358-371 (1979).
20. N. L. Dayneka, V. Garg, and W. J. Jusko. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478 (1993).
21. C. I. Bliss. The toxicity of poissons applied jointly. Ann Appl Biol 26:585-615 (1939).
22. D. M. Jonker, S. A. Visser, P. H. van der Graaf, R. A. Voskuyl, and M. Danhof. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther 106:1-18 (2005).
23. J. Earp, W. Krzyzanski, A. Chakraborty, M. K. Zamacona, and W. J. Jusko. Assessment of drug interactions relevant to pharmacodynamic indirect response models. J Pharmacokinet Pharmacodyn 31:345-380 (2004).
24. Ch. F. Minto, T. W. Schinder, T. G. Short, K. M. Gregg, A. Gentilini, and S. L. Shafer. Response surface model for anesthetic drug interactions. Anesthesiology 92:1603-1616 (2000).
25. M. Gårdmark, and M. Hammarlund-Udenaes. Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat-pharmacokinetic/pharmacodynamic modelling. Pain 74:287-296 (1998).
26. T. P. Enggaard, L. Poulsen, L. Arendt-Nielsen, K. Brosen, J. Ossig, and S. H. Sindrup. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 102:146-150 (2006).
27. M. H. Rashid, M. Inoue, K. Toda, and H. Ueda. Loss of peripheral morphine analgesia contributes to the reduced effectiveness of systemic morphine in neuropathic pain. J Pharmacol Exp Ther 309:380-387 (2004).
28. P. L. Dellemijn, and J. A. Vanneste. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 349:753-758 (1997).
29. J. S. Gimbel, P. Richards, and R. K. Portenoy. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology 60:927-934 (2003).
30. C. P. Watson, and N. Babul. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 50:1837-1841 (1998).
31. J. A. Mico, D. Ardid, E. Berrocoso, and A. Eschalier. Antidepressants and pain. Trends Pharmacol Sci 27:348-354 (2006).
32. R. M. Duhmke, D. D. Cornblath, and J. R. Hollingshead. Tramadol for neuropathic pain. Cochrane Database Syst Rev 2:CD003726 (2004).
33. D. M. Jonker, R. A. Voskuyl, and M. Danhof. Pharmacodynamic analysis of the anticonvulsant effects of Tiagabine and Lamotrigine in combination in the rat. Epilepsia 45:424-435 (2004).
34. T. Ch. Chou. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681 (2006).